We are advancing three late-stage cardiovascular therapies in indications for which no approved therapies currently exist.
Fueled by deep scientific expertise and a passion for helping people with cardiovascular diseases, Kardigan has curated a robust pipeline of late-stage clinical programs, each designed to move beyond symptom management and to redefine treatment approaches where patients and their families need it most.
1 Kardigan in-licensed exclusive worldwide development and commercialization rights to danicamtiv, an investigational drug discovered at MyoKardia and further developed by Bristol Myers Squibb.
2 Kardigan acquired rights to ataciguat, an investigational drug developed by, and in-licensed from, Sanofi and Mayo Clinic.
3 Kardigan in-licensed exclusive worldwide development and commercialization rights to tonlamarsen, an investigational drug discovered and developed by Ionis.